NCT04552613View on ClinicalTrials.gov

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

NACompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

September 24, 2023

Study Completion Date

September 24, 2023

Conditions
Non-small-lung-cell CancerNSCLCEGFR Gene Mutation
Interventions
DRUG

EGFR-TKI

(A) Standard programme group, EGFR-TKI targeted therapy;

DRUG

EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)

(B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )

Trial Locations (1)

310000

China, Zhejiang, Hangzhou

All Listed Sponsors
lead

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

OTHER

NCT04552613 - Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients | Biotech Hunter | Biotech Hunter